<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507439</url>
  </required_header>
  <id_info>
    <org_study_id>19167</org_study_id>
    <nct_id>NCT03507439</nct_id>
  </id_info>
  <brief_title>REALIsM-HF Pilot Study</brief_title>
  <acronym>REALIsM-HF</acronym>
  <official_title>Real Life Multimarker Monitoring in Patients With Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to explore two marketed devices providing a multimarker monitoring including&#xD;
      physical activity under real-life conditions in patients with heart failure with preserved&#xD;
      ejection fraction (HFpEF) and with heart failure and reduced ejection fraction (HFrEF). It&#xD;
      aims to identify potential novel endpoints for future heart failure trials by exploring&#xD;
      clinically relevant changes over time and correlations/associations with conventional&#xD;
      endpoints such as the six minute walking distance (6MWD), biomarkers and clinical events.&#xD;
      Furthermore, it aims to address the challenges and feasibility of implementing device based&#xD;
      measurements under real-life conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Device 1 VitalPatch® biosensor (VitalConnect, USA) Device 2 DynaPort Move Monitor (McRoberts,&#xD;
      NL)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2018</start_date>
  <completion_date type="Actual">March 12, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of daily physical activity</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>measured with the VitalPatch Biosensor/ DynaPort Move Monitor device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of daily physical activity</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>measured with the VitalPatch Biosensor/ DynaPort Move Monitor device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of daily physical activity</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>measured with the VitalPatch Biosensor/ DynaPort Move Monitor device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-minute walking distance (6MWD)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep movements</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>measured with DynaPort Move Monitor device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep patterns</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>measured with DynaPort Move Monitor device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sit-to-stand behaviour</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>measured with DynaPort Move Monitor device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured with the Kansas City Cardiomyopathy Questionnaire score</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>measured using Electronic Patient Research Outcome (ePRO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>NTproBNP, hs-Copeptin, hs-TNT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function parameters measured by echocardiography</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability derived from VitalPatch Biosensor</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA class according to the New York Heart Association Functional Classification</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart failure patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with worsening heart failure (HF) and recent hospitalization for the treatment of HF or patients with chronic stable HF with either preserved (EF ≥ 45%) or reduced ejection fraction (EF ≤ 35%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VitalPatch Biosensor</intervention_name>
    <description>Patients will receive the VitalPatch Biosensor system at 5 monitoring periods</description>
    <arm_group_label>Heart failure patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DynaPort Move Monitor</intervention_name>
    <description>Patients will receive the DynaPort Move Monitor (belt) at 2 monitoring periods</description>
    <arm_group_label>Heart failure patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent signed before any study-specific procedure&#xD;
&#xD;
          -  Men or women aged 45 years and older&#xD;
&#xD;
          -  Established diagnosis of chronic heart failure NYHA class II-IV&#xD;
&#xD;
          -  Worsening heart failure requiring hospitalization for the initiation of&#xD;
             intensification of heart failure therapy with at least one of the following: BNP ≥ 100&#xD;
             pg/mL or NT-proBNP ≥ 400 pg/mL (sinus rhythm) OR BNP ≥ 300 pg/mL or NT-proBNP ≥ 1200&#xD;
             pg/mL (atrial fibrillation) OR Radiographic evidence of pulmonary congestion&#xD;
             (interstitial edema, pulmonary venous hypertension, vascular congestion, pleural&#xD;
             effusion) OR Catheterization documented elevated filling pressures at rest (left&#xD;
             ventricular end-diastolic pressure ≥15 mmHg or pulmonary capillary wedge pressure ≥ 20&#xD;
             mmHg) or with exercise (pulmonary capillary wedge pressure ≥ 25 mmHg)&#xD;
&#xD;
          -  Ambulatory patients with a history of heart failure on individually optimized&#xD;
             treatment with HF medications unless contraindicated or not tolerated, for at least 12&#xD;
             weeks and at least one of the following: a) Hospitalization for heart failure within&#xD;
             the past 12 months OR b) BNP ≥ 100 pg/mL or NT-proBNP ≥ 400 pg/mL (sinus rhythm) OR c)&#xD;
             BNP ≥ 300 pg/mL or NT-proBNP ≥ 1200 pg/mL (atrial fibrillation)&#xD;
&#xD;
          -  For HFrEF only: EF ≤35% assessed by any imaging modality (e.g. echocardiography,&#xD;
             cardiac magnetic resonance, cine levocardiography) within 12 months prior to study&#xD;
             inclusion&#xD;
&#xD;
          -  For HFpEF only: EF ≥45% assessed by any imaging modality (e.g. echocardiography,&#xD;
             cardiac magnetic resonance, cine levocardiography) within 12 months prior to study&#xD;
             inclusion&#xD;
&#xD;
          -  Willingness to wear the DynaPort Move Monitor accelerometer belt and VitalPatch&#xD;
             Biosensor during the trial&#xD;
&#xD;
          -  Body size allows wearing of the accelerometer belt as confirmed by ability to&#xD;
             comfortably fasten the test belt provided for the screening process&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Inability to comply with planned study procedures or to comply with study protocol&#xD;
             requirements; this includes completing required data collection, and attending&#xD;
             required follow up study visits&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 g/dl&#xD;
&#xD;
          -  Acute coronary syndrome or percutaneous coronary intervention within 3 months prior to&#xD;
             informed consent&#xD;
&#xD;
          -  Listing for heart transplantation and / or anticipated implantation of a ventricular&#xD;
             assist device&#xD;
&#xD;
          -  Inability to exercise: wheelchair / scooter / walker dependent; dependent on&#xD;
             supplemental oxygen&#xD;
&#xD;
          -  Known clinically significant persistent coronary ischemia (based on medical history, a&#xD;
             preexisting or a recent clinical stress test)&#xD;
&#xD;
          -  HF is not the primary factor limiting activity within the last three months as&#xD;
             indicated by the patient affirming #1, #2 or #3 of the following questionnaire: My&#xD;
             ability to be active is most limited by: #1 - Joint, foot, leg, hip or back pain; #2 -&#xD;
             Unsteadiness or dizziness impairing daily mobility; #3 - Lifestyle, weather, or I just&#xD;
             don't like to be active&#xD;
&#xD;
          -  Occurrence of any of the following within 3 months prior to informed consent:&#xD;
             Myocardial infarction, Hospitalization for unstable angina, Stroke or transient&#xD;
             ischemic attack, Coronary artery bypass graft (CABG), Percutaneous coronary&#xD;
             intervention (PCI), Implantation of a cardiac resynchronization therapy device (CRTD),&#xD;
             Major surgery (that could interfere with patients' ability to exercise)&#xD;
&#xD;
          -  PCI, CABG or implantation of a CRTD planned between randomization and Visit 4&#xD;
&#xD;
          -  Subject who cannot tolerate placement of external patch monitor on chest in the&#xD;
             proposed location (ECG lead II orientation)&#xD;
&#xD;
          -  Subject with known allergies or hypersensitivities to adhesives or hydrogels&#xD;
&#xD;
          -  Severe uncorrected valvular heart disease&#xD;
&#xD;
          -  Known clinically relevant ventricular arrhythmias (sustained ventricular tachycardia,&#xD;
             ventricular flutter or fibrillation)&#xD;
&#xD;
          -  Severe pulmonary disease with any of the following: Requirement of continuous (home)&#xD;
             oxygen or History of chronic obstructive pulmonary disease ≥ GOLD III&#xD;
&#xD;
          -  Previous (within 30 days or 5 half-lives of the investigational drug, whichever is&#xD;
             longer) or concomitant participation in another clinical study with investigational&#xD;
             medicinal product(s) or device(s)&#xD;
&#xD;
          -  Any condition or therapy, which would make the patient unsuitable for the study, or&#xD;
             life expectancy less than 12 months (e.g. active malignancy)&#xD;
&#xD;
          -  Heavy alcohol consumption or the use of illicit drugs that, in the opinion of the&#xD;
             investigator, may interfere with the patient's safety and / or compliance&#xD;
&#xD;
          -  Patients who regularly (&gt; 1x per week) swim, do water aerobics or go to the sauna,&#xD;
             unwilling to omit this activity while needing to wear the study specific medical&#xD;
             devices&#xD;
&#xD;
          -  Active myocarditis&#xD;
&#xD;
          -  Primary hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Constrictive pericarditis or pericardial tamponade&#xD;
&#xD;
          -  Close affiliation with the investigational site, e.g. a close relative of the&#xD;
             investigator, dependent person (e.g. employee or student of the investigational site)&#xD;
&#xD;
          -  Previous participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich-Heine-Universität Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Campus Virchow-Klinikum (CVK)</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 20, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure with preserved ejection fraction (HFpEF)</keyword>
  <keyword>Heart failure with reduced ejection fraction (HFrEF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

